HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Shu, Xiaoming ^a   Peng, Qinglin ^a   Lu, Xin ^a   Wang, Guochun ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; OVERALL SURVIVAL; POLYMYOSITIS; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; COMPLICATION; DISEASE COURSE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS;

BIOMARKERS; CASE-CONTROL STUDIES; DERMATOMYOSITIS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84984801026     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161436     Document Type: Article

References (35)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292 (8):403-7. doi:10.1056/NEJM197502202920807 PMID: 1089199.
2. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971-82. doi:10.1016/S0140-6736(03)14368-1PMID: 14511932.
3. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: A quantitative study. Ann Neurol. 1990; 27(4):343-56. doi: 10.1002/ana.410270402 PMID: 2353792.
4. Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol. 1991; 48(1):26-30. PMID: 1986724.
5. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol. 1986; 19(2):112-25. doi:10.1002/ana.410190203 PMID: 3008636.
6. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991; 325 (21):1487-98. doi:10.1056/NEJM199111213252107 PMID: 1658649.
7. Sundaram C, Uppin MS, Meena AK. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. Neurol India. 2008; 56(3):363-7. PMID: 18974565.
8. Vitadello M, Doria A, Tarricone E, Ghirardello A, Gorza L. Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation. Arthritis Res Ther. 2010; 12(2):R52. doi:10.1186/ar2963 PMID: 20334640; PubMed Central PMCID: PMCPMC2888201.
9. Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR, et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004; 31(3):605-9. PMID: 14994413.
10. Chauhan AK, Moore TL, Bi Y, Chen C. FcgammaRIIIa-Syk Co-signal Modulates CD4+ T-cell Response and Up-regulate TLR expression. J Biol Chem. 2015.
11. Harris HE, Andersson U, Pisetsky DS. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012; 8(4):195-202. doi:10.1038/nrrheum.2011.222 PMID: 22293756.
12. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5(4):331-42. doi:10.1038/nri1594 PMID: 15803152.
13. Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): An alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther. 2008; 10(3):209. doi:10.1186/ar2440 PMID: 18598385; PubMed Central PMCID: PMCPMC2483460.
14. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13(3):R71. doi:10.1186/ar3332 PMID: 21548924; PubMed Central PMCID: PMCPMC3218880.
15. Grundtman C, Bruton J, Yamada T, Ostberg T, Pisetsky DS, Harris HE, et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J. 2010; 24(2):570-8. doi:10.1096/fj.09-144782 PMID: 19837864.
16. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al. New EMBO members' review: The double life of HMGB1 chromatin protein: Architectural factor and extracellular signal. EMBO J. 2001; 20 (16):4337-40. doi: 10.1093/emboj/20.16.4337 PMID: 11500360; PubMed Central PMCID: PMCPMC125571.
17. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139-62. doi:10.1146/annurev-immunol-030409-101323 PMID: 21219181; PubMed Central PMCID: PMCPMC4536551.
18. Zong M, Bruton JD, Grundtman C, Yang H, Li JH, Alexanderson H, et al. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis. 2013; 72(8):1390-9. doi:10.1136/annrheumdis-2012-202207PMID: 23148306.
19. Kang R, Livesey KM, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 as an autophagy sensor in oxidative stress. Autophagy. 2011; 7(8):904-6. PMID: 21487246.
20. Cseri K, Vincze J, Cseri J, Fodor J, Csernatony Z, Csernoch L, et al. HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases. J Muscle Res Cell Motil. 2015; 36(3):255-62. doi:10.1007/s10974-015-9411-7 PMID: 25761565.
21. Ichikado K, Johkoh T, Ikezoe J, Takeuchi N, Kohno N, Arisawa J, et al. Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. AJR Am J Roentgenol. 1997; 168(2):333-8doi:10.2214/ajr.168.2.9016201PMID: 9016201.
22. Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002; 47(6):614-22. doi:10.1002/art.10794 PMID: 12522835.
23. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients. Arthritis Rheum. 2011; 63(11):3439-47. doi:10.1002/art.30513 PMID: 21702020.
24. Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007; 101 (8):1761-9. doi:10.1016/j.rmed.2007.02.017 PMID: 17428649.
25. Vincze M, Danko K. Idiopathic inflammatory myopathies. Best Pract Res Clin Rheumatol. 2012; 26 (1):25-45. doi:10.1016/j.berh.2012.01.013 PMID: 22424191.
26. De Mori R, Straino S, Di Carlo A, Mangoni A, Pompilio G, Palumbo R, et al. Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol. 2007; 27 (11):2377-83. doi:10.1161/ATVBAHA.107.153429 PMID: 17872450.
27. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285(5425):248-51. Epub 1999/07/10. PMID: 10398600.
28. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005; 115(5):1267-74. doi:10.1172/JCI22782PMID: 15841214; PubMed Central PMCID: PMCPMC1077171.
29. Barnay-Verdier S, Fattoum L, Borde C, Kaveri S, Gibot S, Marechal V. Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. Intensive Care Med. 2011; 37(6):957- 62. Epub 2011/03/02. doi:10.1007/s00134-011-2192-6 PMID: 21359606.
30. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010; 49(9):1726-33. Epub 2010/05/27. doi:10.1093/rheumatology/keq153 PMID: 20501546.
31. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010; 49(3):433-40. Epub 2009/12/18. doi:10.1093/rheumatology/kep375 PMID: 20015976.
32. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49(9):1713-9. Epub 2010/05/26. doi:10.1093/rheumatology/keq149 PMID: 20498012.
33. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013; 107(5):745-52. Epub 2013/03/15. doi:10.1016/j.rmed.2013.01.014 PMID: 23485097.
34. Takahashi M. High-Mobility Group Box 1 Protein in Myocardial Infarction: Should it be Stimulated or Inhibited? J Atheroscler Thromb. 2015; 22(6):553-4. doi:10.5551/jat.ED008 PMID: 25752364.
35. Nakamura Y, Suzuki S, Shimizu T, Miyata M, Shishido T, Ikeda K, et al. High Mobility Group Box 1 Promotes Angiogenesis from Bone Marrow-derived Endothelial Progenitor Cells after Myocardial Infarction. J Atheroscler Thromb. 2015; 22(6):570-81. doi:10.5551/jat.27235 PMID: 25735431.